Trodelvy notch­es a win in most com­mon form of breast can­cer

Fol­low­ing a promise last year to go “big and fast in breast can­cer,” Gilead has se­cured a win for Trodelvy in the most com­mon form.

The drug was ap­proved to treat HR-pos­i­tive, HER2-neg­a­tive breast can­cer pa­tients who’ve al­ready re­ceived en­docrine-based ther­a­py and at least two oth­er sys­temic ther­a­pies for metasta­t­ic can­cer, Gilead an­nounced on Fri­day.

Trodelvy won its first in­di­ca­tion in metasta­t­ic triple-neg­a­tive breast can­cer back in 2020, and has since added urothe­lial can­cer to the list. HR-pos­i­tive HER2-neg­a­tive breast can­cer ac­counts for rough­ly 70% of new breast can­cer cas­es world­wide per year, ac­cord­ing to se­nior VP of on­col­o­gy clin­i­cal de­vel­op­ment Bill Gross­man, and many pa­tients de­vel­op re­sis­tance to en­docrine-based ther­a­pies or wors­en on chemother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER